Patents by Inventor Jürgen Wichmann

Jürgen Wichmann has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • 2H-tetrazole-amide compounds with therapeutic activity as metabotropic glutamate receptor agonists
    Patent number: 6399641
    Abstract: The present invention is a series of 2H-tetrazole-5-yl-amide derivatives showing activity as ligands of metabotropic glutamate receptors.
    Type: Grant
    Filed: June 27, 2001
    Date of Patent: June 4, 2002
    Assignee: Hoffmann-la Roche Inc.
    Inventors: Synese Jolidon, Vincent Mutel, Eric Vieira, Juergen Wichmann
  • Novel 2H-tetrazole-amide compounds with therapeutic activity as metabotropic glutamate receptor agonists
    Publication number: 20020022648
    Abstract: The present invention is a series of 2H-tetrazole-5-yl-amide derivatives showing activity as ligands of metabotropic glutamate receptors.
    Type: Application
    Filed: June 27, 2001
    Publication date: February 21, 2002
    Inventors: Synese Jolidon, Vincent Mutel, Eric Vieira, Juergen Wichmann
  • 1-sulfonyl pyrrolidine derivatives
    Publication number: 20020019424
    Abstract: The present invention is a series of compounds that are derivatives of 1-sulfonyl-pyrrolidine and that demonstrate affinity towards metabotropic glutamate receptors. The invention further relates to medicaments containing these compounds and to a process for their preparation. The compounds possess affinity towards metabotropic glutamate receptors and are therefore useful in the treatment or prevention of acute and/or chronic neurological disorders.
    Type: Application
    Filed: June 13, 2001
    Publication date: February 14, 2002
    Inventors: Vincent Mutel, Juergen Wichmann
  • Serotonin receptor binding benzo[e]isoindoles and benzo[h]isoquinolines
    Patent number: 6310208
    Abstract: Since the compounds in accordance with the invention can bind to serotonin receptors (5HT2), they are especially suitable for the treatment or prevention of central nervous disorders such as depressions, bipolar disorders, anxiety states, sleep and sexual disorders, psychoses, schizophrenia, migraine and other conditions associated with cephalic pain or pain of a different kind, personality disorders or obsessive-compulsive disorders, social phobias or panic attacks, mental organic disorders, mental disorders in childhood, aggressivity, age-related memory disorders and behavioral disorders, addiction, obesity, bulimia etc., nervous system damage caused by trauma, stroke, neurodegenerative diseases etc.; cardiovascular disorders such as hypertension, thrombosis, stroke etc.; and gastrointestinal disorders such as dysfunction of the gastrointestinal tract motility.
    Type: Grant
    Filed: January 6, 1998
    Date of Patent: October 30, 2001
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Michael Bös, Heinz Stadler, Jürgen Wichmann
  • 1-arenesulfonyl-2-aryl-pyrrolidine and pyridine derivatives
    Patent number: 6284785
    Abstract: 1-Arenesulfonyl-2-Aryl-pyrrolidine and pyridine derivatives having activity as ligands of metabotropic glutamate receptors of the formula are disclosed.
    Type: Grant
    Filed: March 24, 2000
    Date of Patent: September 4, 2001
    Assignee: Hoffmann- La Roche Inc.
    Inventors: Vincent Mutel, Eric Vieira, Jürgen Wichmann
  • Heterocyclic vinyl ethers
    Patent number: 6248901
    Abstract: The compounds of the formula wherein R signifies halogen or lower alkyl; n signifies 0-3; R1 signifies lower alkyl; cycloalkyl; benzyl optionally substituted by hydroxy, halogen, lower alkoxy or lower alkyl; benzoyl optionally substituted by amino, lower alkylamino or di-lower alkylamino; acetyl or cycloalkyl-carbonyl; and signifies an aromatic 5-membered residue which is bonded via a N-atom and which contains further 1-3 N atoms in addition to the linking N atom, as well as their pharmaceutically acceptable salts as therapeutically active substances, especially for the control or prevention of acute and/or chronic neurological disorders.
    Type: Grant
    Filed: May 4, 1999
    Date of Patent: June 19, 2001
    Assignee: Hoffman-La Roche Inc.
    Inventors: Geo Adam, Sabine Kolczewski, Vincent Mutel, Heinz Stadler, Jürgen Wichmann, Thomas Johannes Woltering